חוב לטווח קצר להון INmune Bio, Inc. (INMB)

INmune Bio, Inc. (INMB) specializes in Alzheimer's disease therapies, anticipating high margins through drug patenting. The team brings together leading immunologists who are granted autonomy and a profit share. This chart of current quotes on GURU.Markets shows a value of 0.04. However, the risk of a cash crunch and stringent FDA oversight create significant obstacles for pipeline development.

For the biotech startup INmune Bio, Inc. (INMB), which relies on grants and immunotherapy investments, minimizing immediate financial pressure is a critical stability factor. This ratio correlates liabilities with a maturity of up to one year against equity, allowing investors to assess bankruptcy risk or excessive management conservatism through the level of short-term debt to equity.